11/1/11 - DormaTarg awarded SBIR Phase II Grant for $2MM
Dr. Michael Ihnat was awarded an SBIR Phase II Grant for $2MM over two years. This grant will boost the company’s work toward filing an investigational new drug application...read more
12/3/10 - DormaTarg awarded grant to help create technology-based jobs in Oklahoma
DormaTarg, Inc. was one out of five R&D Intern Partnerships funded this week for $236,070 by the Oklahoma Center for the Advancement of Science and Technology (OCAST). Professors from Northwestern Oklahoma State University and the University of Tulsa and representatives of two private sector Oklahoma firms will oversee student interns in the awarded projects...read more
12/2/10 - Dr. Ihnat Awarded OCAST Applied Research Grant for $91,570
The Oklahoma Center for the Advancement of Science and Technology (OCAST) this week awarded $1.9 million to 13 research applicants who are required to match the funding dollar for dollar. The research and development projects will be completed within the next three years...read more
11/1/10 - DormaTarg awarded Qualifying Therapeutic Discovery Project from IRS
DormaTarg, Inc. has been awarded a grant for $173,044 from the Internal Revenue Service under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of the company's lead compounds to treat cancer. The QTDP grant program provides support for innovative projects that are determined by the U.S. Department of Health and Human Services to have reasonable potential to result in a new therapy, reduce health care costs, or significantly advance the goal of curing cancer. Over 5,600 applications were subbmitted for the $1 Billion Fund...read more
4/29/10 - DormaTarg to attend BIO 2010 International Convention in Chicago
More than 70 delegates from Oklahoma’s bioscience industry will represent the state next week at the BIO 2010 International Convention in Chicago. Scientists, business leaders, educators and economic development officers again will seek business connections and to promote the state’s growing bioscience sector...read more
11/20/09 - DormaTarg Awarded Applied Research Grant
OCAST board members have approved $1.8 million for the Oklahoma Applied Research Support program to fund 10 projects chosen on the basis of quality science and expectations for commercialization...read more
10/26/09 - DormaTarg featured at the Bricktown Capital Conference
DormaTarg, Inc. was featured at the University Research Luncheon at the Bricktown Capital Conference as one of the University of Oklahoma's most qualified technology opportunities as a funding-ready candidate...read more
10/2/09 - DormaTarg selected for the Niche Assessment Program (NAP)
DormaTarg was selected as a part of the National Institutes of Health (NIH) Niche Assessment Program to assess the commercial viability of selected SBIR awardees.
8/19/09 - DormaTarg Awarded SBIR Phase I
Dr. Paul Hauser of DormaTarg was awarded an SBIR Phase I grant for $259,133. This award will be used to screen an additional 20,000 compounds through our patented dormant cancer model.
7/20/09 - DormaTarg attends 2009 BIO International Convention
Nick Stefanko and Kris Vermelis of DormaTarg attended the 2009 Bio International Convention in Atlanta, Georgia as a part of the Oklahoma Bioscience Association...read more
DormaTarg awarded fellowship to attend BIO
Nick Stefanko and Kris Vermelis are awarded a fellowship by the Oklahoma Business Roundtable to attend the International BIO Convention...read more
On the Brink Award
Founder Dr. Robert Hurst was honored with the "On the Brink Award" from the Journal Record...read more
Dr. Ihnat Awarded $122,450
Dr. Michael Ihnat was awarded an SBIR Phase I Grant for $122,450.
